Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Am Heart Assoc ; 9(7): e014919, 2020 04 07.
Article in English | MEDLINE | ID: mdl-32212910

ABSTRACT

Background Aerobic exercise capacity is inversely associated with cardiovascular and all-cause mortality in men and women without coronary artery disease (CAD); however, a higher amount of vigorous exercise is associated with a J-shaped relationship in CAD patients. Therefore, the optimal type and amount of exercise for CAD patients is unclear. Coronary artery calcification (CAC) is associated with increased cardiovascular disease (CVD) events and mortality. Fatty plaque is more likely to rupture and cause coronary events than other types. We examined the association between exercise capacity, fatty plaque, CAC score and CVD events in CAD patients. Methods and Results A total of 270 subjects with stable CAD were divided into tertiles based on metabolic equivalents of task (METs) calculated from exercise treadmill testing. Self-reported exercise was obtained. Coronary computed tomographic angiography measured coronary plaque volume and CAC score. After adjustment, fatty plaque volume was not different among the 3 MET groups. For each 1 MET increase, CAC was 66.2 units lower (P=0.017). Those with CAC >400 and ≥8.2 METs had fewer CVD events over 30 months compared to <8.2 METs (P=0.037). Of moderate intensity exercisers (median, 240 min/wk; 78% walking only), 62.4% achieved ≥8.2 METs and lower CAC scores (P=0.07). Intensity and duration of exercise had no adverse impact on coronary plaque or CVD events. Conclusions Achieving ≥8.2 METs with moderate exercise intensity and volume as walking resulted in lower CAC scores and fewer CVD events. Therefore, vigorous exercise intensity and volume may not be needed for CAD patients to derive benefit. Registration URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01624727.


Subject(s)
Cardiorespiratory Fitness , Coronary Artery Disease/physiopathology , Exercise Tolerance , Plaque, Atherosclerotic , Vascular Calcification/physiopathology , Adult , Aged , Aged, 80 and over , Computed Tomography Angiography , Coronary Angiography , Coronary Artery Disease/complications , Coronary Artery Disease/diagnostic imaging , Cross-Sectional Studies , Exercise Test , Female , Heart Disease Risk Factors , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , Randomized Controlled Trials as Topic , Risk Assessment , Rupture, Spontaneous , Severity of Illness Index , Vascular Calcification/complications , Vascular Calcification/diagnostic imaging
2.
J Clin Neuromuscul Dis ; 19(4): 211-216, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29794576

ABSTRACT

Immune-mediated necrotizing myopathy is a very rare inflammatory disease affecting skeletal muscles. Immune-mediated necrotizing myopathy may be associated with myositis-specific autoantibodies including anti-single recognition particle and anti-3-hydroxy-3- methylglutaryl-coenzyme A reductase, infectious agents (HIV or hepatitis C), other connective tissue disorders (such as scleroderma), and malignancy. We reported a 28-year-old healthy woman presented with subacute onset ascending muscle weakness 2 weeks after an annual influenza vaccination. Cerebral Spinal Fluid study showed normal cell counts with elevated protein and nerve conduction study showed reduced diffuse compound muscle action potential amplitudes suggesting a diagnosis of Guillain-Barré syndrome. Despite treatment using intravenous immunoglobulin, her condition continued to get worse with new bulbar and respiratory muscle weakness. Eventually, the diagnosis of anti-single recognition particle-mediated necrotizing myopathy was made based on elevated creatine kinase, thigh magnetic resonance imaging, muscle biopsy, and positive antibody testing. Our patient responded to the combination of intravenous immunoglobulin, prednisone, and anti-CD20 monoclonal antibody, rituximab.


Subject(s)
Immunologic Factors/therapeutic use , Influenza Vaccines/adverse effects , Muscular Diseases/chemically induced , Muscular Diseases/therapy , Neuroprotective Agents/therapeutic use , Adult , Creatine Kinase/blood , Female , Humans , Immunoglobulins, Intravenous/therapeutic use , Magnetic Resonance Imaging , Methylprednisolone Hemisuccinate/therapeutic use , Muscular Diseases/diagnostic imaging , Muscular Diseases/physiopathology , Neural Conduction/physiology , Reaction Time/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...